Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 7050 participants.

Also called NCT07318610

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 7,050 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07318610
  • EU CT 2025-522954-37-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Japan, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07318610. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-10 (actual); primary completion 2029-08-18 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Acronym
ROXI-PALISADE
Condition
Peripheral Artery Disease (PAD)
Intervention (Drug)
REGN7508
Intervention (Drug)
REGN9933
Intervention (Drug)
Placebo
Intervention (Drug)
Rivaroxaban
Lead sponsor
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07318610
Content hash
653bef5660ed60f380a4fd5c1a7348562113a179905295651832551f641a5a17